SYN 114

Drug Profile

SYN 114

Alternative Names: SYN114

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Biotie Therapies Corp.
  • Class Nootropics; Small molecules
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 29 Mar 2011 Discontinued - Phase-I for Cognition disorders in USA (PO)
  • 01 Feb 2011 Synosia Therapeutics has been acquired by Biotie Therapies Corp.
  • 12 Mar 2009 Phase-I development is ongoing for Cognition disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top